Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC) , a biopharmaceutical company specializing in the development of a new class of drugs acting directly on the brain to treat resistant arterial hypertension and heart failure, announces the launch of the REFRESH study in high blood pressure that is difficult to treat (1) or resistant (2) .

This new study is part of the phase III clinical program of firibastat with the objective of demonstrating the long-term safety of the product as well as its efficacy at 3 months, after a single daily dose of 1000 mg.

'We are very happy to be able to launch this pivotal study now with the new dosage form in a once-daily tablet, which will immediately put on the market a form better suited to chronic treatment ', declared Jean-Philippe Milon, CEO of Quantum Genomics, ' This study will also collect long-term safety data, in accordance with the development plan approved by the FDA. ' (3)

This multicenter, multinational study will recruit 750 patients with difficult-to-treat or resistant high blood pressure, in Europe, Canada, the United States and Asia (in collaboration with Quantum Genomics' commercial partners in China, Taiwan and South Korea ).

During a first 3-month randomized double-blind period, 750 patients will receive either firibastat (1000 mg once a day) or a placebo, in addition to their current treatment. The primary endpoint will be the reduction in systolic blood pressure measured automatically in the doctor's office (AOBP) from the baseline. This period will be followed by a phase aimed at verifying the safety of the product over a period of 6 months up to 12 months for 100 patients, mandatory data for the registration of chronic treatment.

The selection of clinical centers will begin and the regulatory files (ethics committees and competent authorities) are being prepared for each country. The recruitment of the first patient will be carried out in the second quarter of 2021 and the efficacy and safety results at 6 months are expected by mid-2023, allowing the filing of marketing authorization applications in 2023. The cost of this The study was budgeted and will be funded through partnerships with Quantum Genomics.

About Quantum Genomics

Quantum Genomics is a biopharmaceutical company specializing in the development of a new class of cardiovascular drugs, based on the mechanism of inhibition of cerebral Aminopeptidase A (Brain Aminopeptidase A Inhibition or BAPAI). The only company in the world to pursue this innovative approach directly targeting the brain, it is based on more than twenty years of research work from the University of Paris-Descartes and the INSERM / CNRS laboratory led by Dr. Catherine Llorens-Cortes at France secondary school. Quantum Genomics thus aims to develop innovative treatments for complicated or even resistant arterial hypertension (around 30% of patients are poorly controlled or have failed treatment), and

Based in Paris and New York, the company is listed on the Euronext Growth market in Paris (FR0011648971 - ALQGC) and listed on the US OTCQX market (symbol: QNNTF).

Contact:

Tel: +1 (617) 535-7746

(C) 2021 Electronic News Publishing, source ENP Newswire